Colleen Wittoesch, Patient and Family Advisor at MD Anderson Cancer Center, shared a post by Cancer Research Institute (CRI) on LinkedIn, adding:
“I am proof that immunotherapy and a phase II clinical trial using immunotherapy for stage 4 metastatic melanoma with brain metastases saves lives!! NED 10 years!
MD Anderson Cancer Center, Only Possible Here!”
Quoting CRI‘s post:
‘When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we’re witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies. These are the breakthroughs that the Cancer Research Institute has championed for decades – supporting the fundamental science that made immunotherapies a reality,’
– emphasizes CRI Scientific Advisory Council member Dr. Antoni Ribas of UCLA.
Continue to discover how immunotherapy is reshaping the odds for cancer patients, in our newest blog post.”
Other articles about Melanoma on OncoDaily.